CVS Health Corp vs Verisign, Inc. — how do they compare? CVS Health Corp trades at $86.85 (market cap $112.29B), while Verisign, Inc. trades at $306.34 (market cap $26.92B). The key difference: CVS Health Corp is far larger — about 4.2× Verisign, Inc.'s market cap, and CVS Health Corp pays the higher dividend (3.03%). Which is the better fit depends on your goals — on Pluang, investors hold CVS Health Corp for 83 Days and Verisign, Inc. for 123 Days on average.
| CVS | VRSN | |
|---|---|---|
Market Cap | $112.29B | $26.92B |
Volume | 7,763,676 | 1,921,402 |
Sector | Health | Technology |
52-Week High | $110.60 | $310.00 |
52-Week Low | $70.08 | $211.49 |
Typical Hold Time | 83 Days | 123 Days |
Enterprise Value | $174.64B | $28.23B |
Dividend Yield | 3.03% | 1.09% |
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $87.95, up 1.76% on the day, with a bullish technical signal and strong analyst support. Recent earnings beats in Q1 and Q2 2026, alongside steady revenue growth to $402.07B in 2025, highlight operational strength. The stock's valuation appears attractive with a P/E of 23.17 and P/S of 0.27, while a consensus price target of $111.20 suggests significant upside potential. Positive news includes Aetna's 2027 Medicare plan enhancements and a declared quarterly dividend.
The outlook for CVS remains positive, driven by earnings momentum and strategic initiatives in healthcare services. Key risks include reimbursement pressures and regulatory scrutiny, but Wall Street's 85% buy rating and institutional interest underscore confidence. Investors should weigh the stock's growth prospects against margin volatility and debt levels, with the current price offering a favorable entry point relative to targets.
VeriSign (VRSN) trades at $301.59, up 2.5% today, with a bullish technical signal and strong institutional buying. The company reported robust Q2 2026 earnings with revenue up 6% year-over-year and EPS of $2.38, though it missed expectations. High profitability is evident with a net income margin near 50%, and cash flow trends are improving. Recent news includes a class-action antitrust lawsuit and insider selling by the CEO, but analyst consensus remains positive.
The outlook is supported by solid fundamentals and a consensus price target of $348, offering ~15% upside. Key risks include legal challenges from the antitrust suit and reliance on domain registration growth. Earnings momentum and institutional accumulation provide tailwinds, but investors should weigh litigation risks against the company's stable cash flows and market position.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →Verisign is the sole authorized registry for several generic top-level domains, including the widely utilized .com and .net top-level domains. The company operates critical Internet infrastructure to support the domain name system, including operating two of the world's 13 root servers that are used to route Internet traffic. In 2018, the firm sold off its Security Services business, signalling a renewed focus on the core registry business.
Read more on VRSN →